Daybue Stix For Solution
Product Images NDC 63090-665

11 FDA label images from Acadia Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Daybue Stix (NDC 63090-665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acadia Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Daybue 01)

Chemical Structure (Daybue 01)
Chemical structure of trofinetide, the active ingredient in Daybue Stix. The diagram shows molecular components and bonds characteristic of trofinetide's chemical composition.*
FDA Label Image

Figure 1 (Daybue 02)

Figure 1 (Daybue 02)
A line graph comparing change from baseline (LSM ± SE) over 12 weeks between Daybue and placebo groups. The x-axis shows study weeks (baseline, 2, 6, 12) and the y-axis shows change from baseline. Daybue shows a larger negative change compared to placebo, with sample sizes provided for each group at each time point below the x-axis.*
FDA Label Image

Figure 2 (Daybue 03)

Figure 2 (Daybue 03)
A bar chart comparing patient percentages by score on the CGI-I scale at week 12 for Daybue (trofinetide) oral solution versus placebo. The x-axis shows scores from 1 (very much improved) to 7 (very much worse), and the y-axis shows the percentage of patients. Daybue shows higher percentages in 'much improved' and 'minimally improved' categories compared to placebo, while placebo has a higher percentage in the 'no change' category.*
FDA Label Image

Principal Display Panel – 450 mL Oral Solution Bottle Label (Daybue 04)

Principal Display Panel – 450 mL Oral Solution Bottle Label (Daybue 04)
Packaging label for Daybue (trofinetide) oral solution 200 mg/mL in a 450 mL bottle. The label includes storage instructions, manufacturer information for Acadia Pharmaceuticals Inc., and usage notes for oral or G-tube administration. It features the Daybue logo with purple and teal design elements.*
FDA Label Image

Principal Display Panel – 450 mL Oral Solution Bottle Carton (Daybue 05)

Principal Display Panel – 450 mL Oral Solution Bottle Carton (Daybue 05)
Carton for Daybue Stix oral solution containing trofinetide 200 mg/mL. The 450 mL package is labeled for refrigeration and proper storage instructions. The labeler is Acadia Pharmaceuticals Inc., with a barcode and recycling symbol present. The design features a purple and teal wave pattern at the bottom and instructions for use by oral or G-tube administration only.*
FDA Label Image

Principal Display Panel – 5,000 mg For Oral Solution Powder Packet (Daybue 06)

Principal Display Panel – 5,000 mg For Oral Solution Powder Packet (Daybue 06)
Label for Daybue Stix (trofinetide) oral solution, marked with a strength of 5,000 mg. The label includes routing instructions for oral or G-tube administration, a warning to keep out of reach of children, and the NDC 63090-663-01. The labeler is Acadia Pharmaceuticals Inc., San Diego, CA. The label features a barcode and batch information space.*
FDA Label Image

Principal Display Panel – 5,000 mg For Oral Solution Powder Carton (Daybue 07)

Principal Display Panel – 5,000 mg For Oral Solution Powder Carton (Daybue 07)
Packaging label for Daybue Stix (trofinetide) for oral solution, 5,000 mg per packet. The label indicates the product is for oral or G-tube administration only, includes 60 packets, and is marketed by Acadia Pharmaceuticals Inc. Storage instructions and dosage directions are provided on the label.*
FDA Label Image

Principal Display Panel – 6,000 mg For Oral Solution Powder Packet (Daybue 08)

Principal Display Panel – 6,000 mg For Oral Solution Powder Packet (Daybue 08)
Label for Daybue Stix 6000 mg trofinetide oral solution from Acadia Pharmaceuticals Inc. The label includes the NDC 63090-664-01, dosage strength of 6000 mg, and administration instructions specifying oral or G-tube use. It also advises keeping the product out of reach of children and includes a barcode.*
FDA Label Image

Principal Display Panel – 6,000 mg For Oral Solution Powder Carton (Daybue 09)

Principal Display Panel – 6,000 mg For Oral Solution Powder Carton (Daybue 09)
Packaging label for Daybue Stix (trofinetide) oral solution, 6,000 mg per packet. The box contains 60 packets intended for oral or G-tube administration. Marketed by Acadia Pharmaceuticals Inc., the label includes instructions to dissolve each packet in 15 to 60 mL of liquid before use. The label features the product name, strength, quantity, usage directions, storage instructions, and barcode.*
FDA Label Image

Principal Display Panel – 8,000 mg For Oral Solution Powder Packet (Daybue 10)

Principal Display Panel – 8,000 mg For Oral Solution Powder Packet (Daybue 10)
The packaging label for Daybue Stix (trofinetide) oral solution, 8,000 mg strength. This human prescription drug by Acadia Pharmaceuticals Inc. is intended for oral or G-tube administration and includes a barcode and NDC number 63090-665-01. The label contains usage and storage instructions.*
FDA Label Image

Principal Display Panel – 8,000 mg For Oral Solution Powder Carton (Daybue 11)

Principal Display Panel – 8,000 mg For Oral Solution Powder Carton (Daybue 11)
Packaging label for Daybue Stix (trofinetide) oral solution, 8,000 mg per packet. The box contains 60 packets for oral or G-tube administration only. Label indicates storage instructions and marketing by Acadia Pharmaceuticals Inc., with green and purple design elements on a white background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.